http://oldabcuro.golins.com/uncategorized/abcuro-initiates-phase-1-2-trial-evaluating-abc008-in-patients-with-t-cell-large-granular-lymphocytic-leukemia/ 2023-06-12T01:07:00+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-alex-martin-as-chief-executive-officer/ 2023-06-12T01:07:51+00:00 http://oldabcuro.golins.com/uncategorized/dietmar-berger-m-d-ph-d-joins-abcuro-therapeutics-as-board-observer/ 2023-06-12T01:08:12+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-h-jeffrey-wilkins-m-d-as-chief-medical-officer/ 2023-06-12T01:08:42+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-presents-additional-data-from-ongoing-phase-1-clinical-trial-of-abc008-in-inclusion-body-myositis-ibm-at-gcom-2022/ 2023-06-12T01:09:24+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-to-present-late-breaking-abstract-at-american-college-of-rheumatology-convergence-2021-of-abc008-inclusion-body-myositis-phase-1-data-demonstrating-proof-of-mechanism-for-selective-depletion-of/ 2023-06-12T01:09:51+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-darlene-deptula-hicks-to-its-board-of-directors/ 2023-06-12T01:10:15+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-to-present-trial-in-progress-poster-on-a-phase-1-clinical-trial-of-abc008-demonstrating-targeted-depletion-of-large-granular-lymphocytes-at-the-2021-leukemia-lymphoma-and-myeloma-congress/ 2023-06-12T01:10:51+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-and-imaginab-share-initial-results-of-study-using-novel-technology-for-imaging-t-cell-infiltration-of-skeletal-muscle-in-patients-with-inclusion-body-myositis/ 2023-06-12T01:11:14+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-raises-42-million-in-series-a-1-financing-appoints-john-b-edwards-as-executive-chair-of-the-board-of-directors-and-david-de-graaf-ph-d-as-chief-executive-officer/ 2023-06-12T01:11:29+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-granted-orphan-drug-designation-for-abc008-for-inclusion-body-myositis/ 2023-06-12T01:11:46+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-to-present-two-posters-at-the-american-academy-of-neurology-2025-annual-meeting/ 2025-03-11T10:55:43+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-announces-200-million-series-c-financing-to-advance-its-first-in-class-medicine-in-development-for-inclusion-body-myositis/ 2025-03-10T18:06:58+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-announced-participation-in-upcoming-investor-conferences/ 2025-03-10T18:10:32+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-announces-participation-in-upcoming-investor-conferences/ 2025-03-10T18:10:49+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-sarah-boyce-to-its-board-of-directors/ 2025-03-10T18:11:07+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-completes-enrollment-of-registrational-phase-2-3-muscle-clinical-trial-of-ulviprubart-for-the-treatment-of-inclusion-body-myositis/ 2025-03-10T18:11:34+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-mark-pruzanski-m-d-as-chairman-of-its-board-of-directors/ 2025-03-10T18:11:55+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-initiates-part-b-of-registrational-phase-2-3-muscle-clinical-trial-of-ulviprubart-abc008-for-the-treatment-of-inclusion-body-myositis/ 2025-03-10T18:12:15+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-announces-155-million-oversubscribed-series-b-financing-to-further-advance-autoimmune-pipeline/ 2025-03-10T18:12:35+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-completes-enrollment-of-sentinel-cohort-in-phase-2-3-study-of-abc008-for-the-treatment-of-inclusion-body-myositis/ 2025-03-10T18:12:55+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-initiates-registrational-phase-2-3-study-of-abc008-for-the-treatment-of-inclusion-body-myositis/ 2025-03-10T18:13:13+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-courtney-cupples-as-chief-commercial-officer/ 2025-06-09T10:50:26+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-appoints-george-eldridge-as-chief-financial-officer/ 2025-08-18T10:45:33+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-to-present-interim-phase-1-data-evaluating-ulviprubart-in-patients-with-t-cell-large-granular-lymphocytic-leukemia-at-the-67th-american-society-of-hematology-annual-meeting/ 2025-11-03T14:42:50+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-presents-interim-phase-1-data-evaluating-ulviprubart-in-patients-with-t-cell-large-granular-lymphocytic-leukemia-at-the-67th-american-society-of-hematology-annual-meeting/ 2025-12-08T16:55:59+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-announces-topline-results-from-the-muscle-study-of-ulviprubart-in-patients-with-inclusion-body-myositis/ 2026-02-24T11:55:29+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-presents-results-from-phase-2-3-muscle-study-of-ulviprubart-in-patients-with-inclusion-body-myositis-at-gcom-2026/ 2026-03-26T14:00:36+00:00 http://oldabcuro.golins.com/uncategorized/abcuro-announces-66-million-series-d-financing-to-advance-its-first-in-class-medicine-in-development-for-inclusion-body-myositis/ 2026-08-18T10:55:34+00:00